Results 41 to 50 of about 50,518 (225)

ERA OF CONJUGATE VACCINES: INTERNATIONAL EXPERIENCE OF SUCCESSFUL APPLICATION

open access: yesПедиатрическая фармакология, 2008
The article highlights comparative characteristics of the polysaccharide and conjugate vaccines against pneumococcal infection, meningococcosis and haemophilus influenza. The author stresses the advantage of the conjugate vaccines.
M.V. Fedoseenko   +2 more
doaj   +2 more sources

Setting priorities for development of emerging interventions against childhood pneumonia, meningitis and influenza [PDF]

open access: yes, 2012
WAcute lower respiratory infections, which broadly include pneumonia and bronchiolitis, are still the leading cause of childhood mortality. ALRI contributed to 18% of all deaths in children younger than five years of age in 2008, and the main pathogens ...
Black   +21 more
core   +3 more sources

Trends in hospitalizations for vaccine‐preventable diseases in the United States from 2014 to 2024

open access: yesJournal of Hospital Medicine, EarlyView.
Abstract Background and Objectives Vaccination rates have declined in recent years, resulting in outbreaks of vaccine‐preventable diseases (VPDs) among children. We aimed to evaluate VPD hospitalization rates from 2014 to 2024 and to report associated trends in outcomes including intensive care utilization, mortality, readmissions, and costs.
Nathan M. Money   +5 more
wiley   +1 more source

Next-Generation Whole-Cell Pneumococcal Vaccine

open access: yesVaccines, 2019
Streptococcus pneumoniae remains a major public health hazard. Although Pneumococcal Conjugate Vaccines (PCVs) are available and have significantly reduced the rate of invasive pneumococcal diseases, there is still a need for new vaccines with unlimited ...
Victor Morais   +2 more
doaj   +1 more source

Refractory Eczema as a Presenting Feature of Common Variable Immunodeficiency

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Common variable immunodeficiency (CVID) is the most prevalent symptomatic inborn error of immunity (IEI) in adults. It presents with recurrent infections and non‐infectious complications, including autoimmunity, lymphoproliferation and dermatitis.
Mercedes Sanchez‐Diaz   +2 more
wiley   +1 more source

New Vaccines for the Prevention of Pneumococcal Infections

open access: yesEmerging Infectious Diseases, 1996
Streptococcus pneumoniae is a major cause of acute otitis media, pneumonia, bacteremia, and meningitis. Because in recent years antibiotic-resistant pneumococcal strains have been emerging throughout the world, vaccination against pneumococcal infections
Helena Käyhty, Juhani Eskola
doaj   +1 more source

Polysaccharide pneumococcal vaccines

open access: yesBMJ, 2002
Infection with Streptococcus pneumoniae (pneumococcus) is a leading cause of illness in young children and of illness and death in elderly people and people with immune deficiencies and chronic illness. Pneumococcus causes a spectrum of disease: infections of the upper respiratory tract, otitis media, invasive infections such as bacteraemia and ...
Tom, Jefferson, Vittorio, Demicheli
openaire   +3 more sources

The Political Economy of Patent Buyouts

open access: yesThe RAND Journal of Economics, EarlyView.
ABSTRACT Incentivizing innovation through buyouts may alleviate the social costs associated with patent power, but the political economy and feasibility of this potentially important financing mechanism have been understudied. We study an international setting of countries with different innovation and financing capabilities, and where financing ...
Amal Ahmad   +2 more
wiley   +1 more source

Variation at the capsule locus, cps, of mistyped and non-typable Streptococcus pneumoniae isolates [PDF]

open access: yes, 2012
The capsule polysaccharide locus (cps) is the site of the capsule biosynthesis gene cluster in encapsulated Streptococcus pneumoniae. A set of pneumococcal samples and non-pneumococcal streptococci from Denmark, the Gambia, the Netherlands, Thailand, the
Antonio, M   +10 more
core   +1 more source

Cost-Effectiveness of 20-Valent Pneumococcal Conjugate Vaccine Among US Children with Underlying Medical Conditions

open access: yesInfectious Diseases and Therapy
Introduction A 20-valent pneumococcal conjugate vaccine (PCV20) was recently recommended for use among US children. We evaluated the cost-effectiveness of PCV20 among children aged 6 years with chronic medical conditions (CMC+) and children aged 6 years ...
Mark H. Rozenbaum   +11 more
doaj   +1 more source

Home - About - Disclaimer - Privacy